J&J gets US subpoenas on marketing of three drugs

CHICAGO, March 12 (Reuters) - Johnson & Johnson (JNJ.N) on Monday said it received three subpoenas from U.S. attorneys related to sales and marketing of three of its prescription drugs.

The drugmaker said the subpoenas, from the U.S. Attorneys in Philadelphia, Boston and San Francisco, relate to previously disclosed probes over the company's oversight of three of its subsidiaries.

The drugs being investigated are Risperdal, Topamax, and Natrecor.

((Reporting by Kim Dixon, editing by Gerald E. McCormick; Reuters Messaging; kim.dixon.reuters.com@reuters.net; email; kim.dixon@reuters.com, 1-312 408 8561))

((Multimedia versions of Reuters Top News are now available for: * 3000 Xtra: visit topnews.session.rservices.com * BridgeStation: view story .134 For more information on Top News: topnews.reuters.com)) Keywords: JNJ SUBPOENA/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWEN5304